• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Role of methyle blue in the management of mild, moderate and severe COVID-19 disease.

作者信息

Bawaskar Himmatrao Saluba, Bawaskar Pramodini Himmatrao

机构信息

Department of Medicine, Bawaskar Hospital and Clinical Research Centre, Mahad, Raigad, Maharashtra.

出版信息

J Family Med Prim Care. 2022 Feb;11(2):812-814. doi: 10.4103/jfmpc.jfmpc_2071_21. Epub 2022 Feb 16.

DOI:10.4103/jfmpc.jfmpc_2071_21
PMID:35360806
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8963598/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9d7/8963598/b21fc4b942e0/JFMPC-11-812-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9d7/8963598/cec2c9c55621/JFMPC-11-812-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9d7/8963598/b21fc4b942e0/JFMPC-11-812-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9d7/8963598/cec2c9c55621/JFMPC-11-812-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9d7/8963598/b21fc4b942e0/JFMPC-11-812-g002.jpg

相似文献

1
Role of methyle blue in the management of mild, moderate and severe COVID-19 disease.亚甲蓝在轻、中、重度新型冠状病毒肺炎治疗中的作用
J Family Med Prim Care. 2022 Feb;11(2):812-814. doi: 10.4103/jfmpc.jfmpc_2071_21. Epub 2022 Feb 16.
2
Retraction: Role of methyle blue in the management of mild, moderate and severe COVID-19 disease.撤稿声明：亚甲蓝在轻度、中度和重度新冠肺炎治疗中的作用
J Family Med Prim Care. 2022 Oct;11(10):6615. doi: 10.4103/2249-4863.359352. Epub 2022 Oct 31.
3
Leaf Juice on Mild and Moderate COVID-19 Patients: Implications in OMICRON Era.叶汁对轻症和中症新冠肺炎患者的影响：在奥密克戎时代的意义
Euroasian J Hepatogastroenterol. 2022 Jan-Jun;12(1):10-18. doi: 10.5005/jp-journals-10018-1367.
4
Efficacy and Safety of Complementary Therapy With Jing Si Herbal Tea in Patients With Mild-To-Moderate COVID-19: A Prospective Cohort Study.静思花草茶辅助治疗轻至中度新冠肺炎患者的疗效与安全性：一项前瞻性队列研究
Front Nutr. 2022 Mar 14;9:832321. doi: 10.3389/fnut.2022.832321. eCollection 2022.
5
Prediction of the Rehabilitation Duration and Risk Management for Mild-Moderate COVID-19.预测轻度至中度 COVID-19 的康复时间和风险管理。
Disaster Med Public Health Prep. 2020 Oct;14(5):652-657. doi: 10.1017/dmp.2020.214. Epub 2020 Jun 24.
6
[Comparison of Recovery Phase CT Features between Mild/moderate and Severe/critical Coronavirus Disease 2019 Patients].[2019年冠状病毒病轻症/中症与重症/危重症患者恢复期CT特征比较]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2020 Jun 30;42(3):370-375. doi: 10.3881/j.issn.1000-503X.12691.
7
Analysis of blood samples from 42 patients with varying degrees of infection during the epidemic of COVID-19: a retrospective study.分析了 42 例 COVID-19 流行期间不同程度感染患者的血样：一项回顾性研究。
Ann Palliat Med. 2022 Jun;11(6):2093-2099. doi: 10.21037/apm-22-658.
8
Prone position reduces the risk of patients with mild or moderate COVID-19 progressing to severe or even critical cases: a retrospective study.俯卧位可降低轻症或普通型 COVID-19 患者向重症甚至危重症进展的风险：一项回顾性研究。
Eur J Med Res. 2022 Aug 12;27(1):149. doi: 10.1186/s40001-022-00776-y.
9
Health-related quality of life among persons with initial mild, moderate, and severe or critical COVID-19 at 1 and 12 months after infection: a prospective cohort study.感染后 1 个月和 12 个月时初始轻度、中度、重度或危重症 COVID-19 患者的健康相关生活质量：一项前瞻性队列研究。
BMC Med. 2022 Nov 2;20(1):422. doi: 10.1186/s12916-022-02615-7.
10
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.用于评估非住院轻中度 COVID-19 患者肠道微生物组调节的自然史和影响的虚拟化临床研究：一项随机、开放标签、前瞻性研究，平行组研究评估 KB109 对肠道微生物组结构和功能的生理影响：一项随机对照研究方案的结构化总结。
Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0.

引用本文的文献

1
The critical impacts of cytokine storms in respiratory disorders.细胞因子风暴在呼吸系统疾病中的关键影响。
Heliyon. 2024 Apr 17;10(9):e29769. doi: 10.1016/j.heliyon.2024.e29769. eCollection 2024 May 15.
2
Retraction: Role of methyle blue in the management of mild, moderate and severe COVID-19 disease.撤稿声明：亚甲蓝在轻度、中度和重度新冠肺炎治疗中的作用
J Family Med Prim Care. 2022 Oct;11(10):6615. doi: 10.4103/2249-4863.359352. Epub 2022 Oct 31.
3
Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19.

本文引用的文献

1
Methylene blue may have a role in the treatment of COVID-19.亚甲蓝可能在治疗 COVID-19 中具有一定作用。
Med Hypotheses. 2020 Nov;144:110163. doi: 10.1016/j.mehy.2020.110163. Epub 2020 Aug 6.
2
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.COVID-19 患者的激肽释放酶-激肽系统阻断治疗以预防急性呼吸窘迫综合征。
Elife. 2020 Apr 27;9:e57555. doi: 10.7554/eLife.57555.
3
Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic.
亚甲蓝是一种非特异性蛋白质-蛋白质相互作用抑制剂，具有重新用作COVID-19抗病毒药物的潜力。
Pharmaceuticals (Basel). 2022 May 18;15(5):621. doi: 10.3390/ph15050621.
COVID-19 大流行期间纤维化间质性肺疾病的诊断和治疗的实际考虑。
Chest. 2020 Sep;158(3):1069-1078. doi: 10.1016/j.chest.2020.04.019. Epub 2020 Apr 22.
4
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
5
Methylene blue: revisited.亚甲蓝：再探讨
J Anaesthesiol Clin Pharmacol. 2010 Oct;26(4):517-20.